# Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.

> **NCT05343819** · PHASE1 · COMPLETED · sponsor: **Aptarion Biotech AG** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AON-D21
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05343819
- **Lead sponsor:** Aptarion Biotech AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-12
- **Primary completion:** 2022-11-29
- **Final completion:** 2022-11-29
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05343819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05343819, "Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05343819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*